News Archive Archives - Vivoryon

Probiodrug to attend and present at International Conferences in February 2017

HALLE (SAALE), Germany, 02 February 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer’s disease patients

HALLE (SAALE), Germany, 09 January 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces that recruitment […]

Probiodrug to attend International Conferences in January 2017

HALLE (SAALE), Germany, 04 January 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Innovative Phase II study design of Glutaminylcyclase Inhibitor PQ912 in early Alzheimer’s disease

Poster presentation at CTAD, San Diego, 8-10 December 2016 HALLE (SAALE), Germany, 8 December 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing […]

Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer’s mouse model

HALLE (SAALE), Germany, 16 November 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced today […]

Probiodrug to attend US Life Sciences Conferences in November 2016

HALLE (SAALE), Germany, 14 November 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), is scheduled to […]

Probiodrug reports Third Quarter 2016 Business Update

HALLE (SAALE), Germany, 10 November 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]

Probiodrug AG to Publish its Third Quarter 2016 Business Update on 10 November 2016

HALLE (SAALE), Germany, 3 November 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]

Probiodrug to present at European Life Sciences Conferences

Attendance at key conferences in November 2016 HALLE (SAALE), Germany, 27 October 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]